Objective: To explore the effect of a new intervention model based on tertiary hospital-close medical union-family doctor graded education guidance on cardiovascular disease risk in patients with type 2 diabetes mellitus. Methods: From the retirees managed by the municipal social security center from 2014 to 2015, type 2 diabetes patients contracted by the hospital's close medical association were selected and divided into intervention group and control group. On the basis of community management, the intervention group was given one-year systematic individualized lifestyle intervention by specialists and nurses, while the control group only received routine community management. Community family doctors were trained twice a year by the specialized team of the tertiary hospital. A total of 456 patients with T2DM whose data were complete were finally studied, including 282 females and 174 males, with an average age of(61.82±0.35) years; among them, 168 were in the intervention group and 288 in the control group. The biochemical indexes and cardiovascular disease progression were compared between the two groups before and after follow-up intervention. Results: (1) After the intervention, the blood glucose, blood lipid and blood pressure of all patients decreased significantly compared with the baseline(P<0.05);(2) There was no significant increase in LDL-C in the intervention group compared to the control group;(3) The risk of coronary heart disease in the control group was 2.53 times higher than that in the intervention group(P<0.05);(4) The renal function in the intervention group declined slowly, and after correcting the confounding factors, lifestyle intervention was an independent protective factor for the decline in renal function(P<0.05). Conclusion: The new intervention mode based on tertiary hospital-close medical union-family doctor graded education guidance can effectively reduce the risk of cardiovascular disease in patients with type 2 diabetes. |
[1] 中国老年2型糖尿病防治临床指南编写组,中国老年医学学会老年内分泌代谢分会,中国老年保健医学研究会老年内分泌与代谢分会,等.中国老年2型糖尿病防治临床指南(2022年版)[J].中华内科杂志,2022,61(1):39.
[2] MOSENZON O, ALGUWAIHES A, LEON J L A, et al.CAPTURE:a multinational,cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries[J].Cardiovasc Diabetol,2021,20(1):154.
[3] PATEL A, MACMAHON S, CHALMERS J, et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2008,358(24):2560-2572.
[4] DUCKWORTH W,ABRAIRA C,MORITZ T,et al.Glucose control and vascular complications in veterans with type 2 diabetes[J].N Engl J Med,2009,360(2):129-139.
[5] 王金平,陈燕燕,巩秋红,等.糖尿病和心血管病预防的破冰之旅——大庆糖尿病预防研究30年[J].中国科学(生命科学),2018,48(8):902-908.
[6] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.稳定性冠心病基层诊疗指南(2020年)[J].中华全科医师杂志,2021,20(3):265-273.
[7] KNUUTI J,WIJNS W,SARASTE A,et al.2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J,2020,41(3):407-477.
[8] KALANTAR-ZADEH K, AMIN A N.Toward more accurate detection and risk stratification of chronic kidney disease[J].JAMA,2012,307(18):1976-1977.
[9] International Diabetes Federation.IDF Diabetes Atlas. 8th Edition, International Diabetes Federation, Brussels[EB/OL]. http://www.diabetesatlas.org/resources/2017-atlas.html.
[10] LEE T T,CHENG S H,CHEN C C,et al.A pay-for-performance program for diabetes care in Taiwan:a preliminary assessment[J].Am J Manag Care,2010;16(1):65-69.
[11] TAYLOR K S,HENEGHAN C J,FARMR A J,et al.All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K.primary care database[J].Diabetes Care,2013,36:2366-2371.
[12] LEAN M E J,LESLIE W S,BARNES A C,et al.Durability of a primary care-led weight-management intervention for remission of type 2 diabetes:2-year results of the DiRECT open-label,cluster-randomised trial[J].Lancet Diabetes Endocrinol,2019,7(5):344-355.
[13] LIU G,LI Y,HU Y,et al.Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus[J].J Am Coll Cardiol,2018,71(25):2867-2876.
[14] GONG Q, ZHANG P, WANG J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study[J]. Lancet Diabetes Endocrinol,2019,7(6):452-461.
[15] LI Q,WANG X,NI Y,et al.Epidemiological characteristics and risk factors of T2DM in Chinese premenopausal and postmenopausal women[J].Lipids in Health and Disease,2019,18:155.
[16] 刘利群.推进家庭医生签约服务加强分级诊疗制度建设[J].中国全科医学,2018,21(1):1-4.
[17] 赵楠,金莉萍,方金赢,等.基于医联体的糖尿病足智能诊疗平台的构建与实践[J].中华糖尿病杂志,2021,13(9):901-905.
[18] 北京大学医学系糖尿病肾脏病专家共识协作组.糖尿病肾脏病诊治专家共识[J].中华医学杂志,2020,100(4):247-260.
[19] 孙雪.2型糖尿病病人慢性肾脏病与心血管风险的相关性研究[D].杭州:浙江大学,2016.
[20] GONG Q,GREGG E W,WANG J,et a1.Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvaseular complications:the China Da Qing Diabetes Prevention Outcome Study[J].Diabetologia,2011,54:300-307.
[21] 陈霞,刘雅.三种新型降糖药物的肾脏保护作用及安全性研究进展[J].山东医药,2019,59(32):5. |